STERIS plc (NYSE:STE), a leader in sterilization and infection prevention, has recently been in news over diverse matters. While investors are speculating if the stock is undervalued by around 42%, recent earnings report presents a solid picture with Q2 revenue hitting $1.3 billion. Despite these strong numbers, the company's stock performance has not outperformed the market consistently. Its healthcare segment has led a 9% surge in Q2 earnings which seems to have appealed to World Investment Advisors, who made a new investment worth $5.17 million. However, analysis also suggests margin pressures and potential weakness in the market. The company maintains its popularity among investors and has recently been retained in various portfolios. Several firms like Hantz Financial Services and The Manufacturers Life Insurance Company have reportedly reduced their holdings in STERIS. Despite macroeconomic issues, new strategic alliances are expected to support the stock's future. Recent developments include the company selling its dental segment to HuFriedy Group and buying Surgical Instrumentation assets from Becton, Dickinson and Company. Lastly, the company will be selling its renal care business for $196 million despite an 11% ROCE reported by the company.
Steris Plc STE News Analytics from Wed, 24 Jun 2015 07:00:00 GMT to Sat, 28 Dec 2024 06:29:04 GMT -
Rating 3
- Innovation 4
- Information 7
- Rumor 4
